Radioactive iodine therapy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 5, 2012, Pages 420-428

  Lee, Stephanie L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hyperthyroidism; radioactive iodine; thyroid cancer

Indexed keywords

IODINE 131; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE;

ABLATION THERAPY; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERTHYROIDISM; MEDICAL DECISION MAKING; REVIEW; THYROID CANCER; THYROID CARCINOMA;

ABLATION TECHNIQUES; FEMALE; GUIDELINES AS TOPIC; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; PATIENT SELECTION; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; UNITED STATES;

EID: 84865994722     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328357fa0c     Document Type: Review

References (62)

1. Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology VII. The use of radioactive iodine therapy in hyperthyroidism. JAMA 1946; 131:81.
2. Chapman E, Evans R. The treatment of hyperthyroidism with radioactive iodine. JAMA 1946; 131:86.
3. Seldin S, Marinelli L, Oshry E. Effect on functioning metastases of adenocarcinoma of thyroid. JAMA 1946; 132:837-847.
4. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542-550.
5. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17:456-520.
6. Fast S, Hegedus L, Grupe P, et al. Recombinant human thyrotropin- stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab 2010; 95:3719-3725.
7. Bonnema SJ, Hegedus L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes 2009; 16:379-384.
8. Fast S, Nielsen VE, Grupe P, et al. Prestimulation with recombinant human Thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab 2012.
9. Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 2011; 21:335-346.
10. Hennessey JV, Parker JA, Kennedy R, Garber Jr. Comments regarding Practice Recommendations of the American Thyroid Association for radiation safety in the treatment of thyroid disease with radioiodine. Thyroid 2012; 22:336-337.
11. Tallstedt L, Lundell G, Tørring O, Wallin G. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326:1733-1738.
12. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalomopathy after radioioidne therapy for hyperthyroidism. N Engl J Med 1989; 321:1349-1352.
13. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338:73-78.
14. Bartalena L. Prevention of Graves' ophthalmopathy. Best pract Res Clin Endocrinol Metab 2012; 26:371-379.
15. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010; 95:1333-1337.
16. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007; 334:514.
17. Burch HB, Solomon BL, Cooper DS, et al. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab 2001; 86:3016-3021.
18. Kubota S, Ohye H, Yano G, et al. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease. Endocr J 2006; 53:603-607.
19. Bonnema SJ, Bennedbaek FN, Veje A, et al. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab 2006; 91:2946-2951.
20. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004; 14:525-530.
21. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87:1073-1077.
22. US Food and Drug Administration. Information for Healthcare Professionals -Propylthiouracil-Induced Liver Failure, June 4, 2009. DOI: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm.
23. Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673-674.
24. Pearce EN, Pino S, He X, et al. Sources of dietary iodine: bread, cows' milk, and infant formula in the Boston area. J Clin Endocrinol Metab 2004; 89:3421-3424.
25. Sawka AM, Ibrahim-Zada I, Galacgac P, et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well differentiated thyroid cancer: a systematic review. Thyroid 2010; 20:1129-1138.
26. Lakshmanan M, Schaffer A, Robbins J, et al. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med 1988; 13:866-868.
27. de Rooij A, Vandenbroucke JP, Smit JW, et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009; 161:771-777.
28. Jarlov AE, Hegedus L, Kristensen LO, et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995; 43:325-329.
29. Peters H, Fischer C, Bogner U, et al. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25:186-193.
30. Kristoffersen US, Hesse B, Rasmussen AK, Kjaer A. Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 h radioiodine uptake. Clin Physiol Funct Imaging 2006; 26:167-170.
31. Sztal-Mazer S, Yumi N, Bortolini L, et al. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioiodine doses. Thyroid. Publsihed online before print June 2012. doi: 10.1089/thy.2011-0362. 2012.
32. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84:499-503.
33. Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 2010; 95:201-208.
34. Chiovato L, Santini F, Vitti P, et al. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clin Endocrinol (Oxf) 1994; 40:803-806.
35. Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropinblocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83:40-46.
36. Graf H, Fast S, Pacini F, et al. Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebocontrolled study. J Clin Endocrinol Metab 2011; 96:1368-1376.
37. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
38. Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure. Clin Nucl Med 2011; 36:440-445.
39. Gabriel S, Farman-Ara B, Bourrelly M, et al. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure. Nucl Med Commun 2011; 32:829-833.
40. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976; 42:105-111.
41. Liu YY, van der Pluijm G, Karperien M, et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin Endocrinol (Oxf) 2006; 64:617-624.
42. Van Nostrand D, Neutze J, Atkins F. Side effects of 'rational dose' iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J Nucl Med 1986; 27:1519-1527.
43. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 2010; 8:1277-1286; quiz 87.
44. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well differentiated thyroid cancer. Thyroid 2009; 19:1381-1391.
45. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 2006; 163:521-527.
46. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93:504-515.
47. Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008; 14:764-774.
48. Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well differentiated thyroid cancer. Cancer Control 2011; 18:89-95.
49. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366:1663-1673.
50. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366:1674-1685.
51. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3542-3546.
52. Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000; 30:98-106.
53. Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94:4171-4179.
54. Hanscheid H, LassmannM, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47:648-654.
55. Donahue KP, Shah NP, Lee SL, Oates ME. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. Radiology 2008; 246:887-894.
56. Lassmann M, Hanscheid H, Verburg FA, Luster M. The use of dosimetry in the treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2011; 55:107-115.
57. Chiesa C, Castellani MR, Vellani C, et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009; 53:546-561.
58. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937-941.
59. Maxon HR 3rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
60. Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010; 20:257-263.
61. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006; 47:1587-1591.
62. Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 2011; 96:2105-2111.